申请人:Universite de Rouen
公开号:US20190345098A1
公开(公告)日:2019-11-14
The invention relates to the field of resolution of chiral compounds existing in the form of two optical antipodes (enantiomers), such as Baclofen. More particularly, the invention relates to the production of the pure enantiomer (R)(−) Baclofen, of chemical nomenclature (R)-4-amino-3-(4-chlorophenyl)-butanoic acid, and the hydrogen maleate salt thereof. More specifically, the invention relates to the resolution of hydrogen maleate salts of racemic Baclofen by preferential crystallisation and particularly by the AS3PC method (auto-seeded and programmed polythermal preferential crystallisation).
本发明涉及手性化合物的分离领域,其以两种光学异构体(对映异构体)的形式存在,例如巴氯芬。更具体地,本发明涉及制备纯对映异构体(R)(−)巴氯芬,化学命名为(R)-4-氨基-3-(4-氯苯基)-丁酸及其氢马来酸盐。更具体地,本发明涉及通过优先结晶和特别是AS3PC方法(自动种子和程序化多温度优先结晶)来分离混合物巴氯芬的氢马来酸盐。